Introduction: Milk kefir, a fermenting milk made with kefir grains, has shown potential in promoting apoptosis, regulating the cell cycle, and reducing tumor growth in breast cancer cells. This study aimed to investigate the stability and potential of milk kefir metabolites as inhibitors of breast cancer growth by interacting with the estrogen receptor alpha (ER-α), a key protein involved in breast cancer cell proliferation. We used computational methods, specifically molecular docking simulations with AutoDock and molecular dynamics (MD) simulations with Gromacs, to analyze how these metabolites bind to ER-α. Methods: A combination of molecular docking and MD simulations was used to explore how metabolites derived from milk kefir interact with ER-α, a crucial target in breast cancer therapy. The methodology included multiple stages: preparation of target proteins, preparation and screening of the metabolites, geometry optimization, molecular docking, and MD simulations. Results: The molecular docking simulations of 43 metabolites revealed three promising candidates: 2-Methyl (S35), benzeneethanol (S42), and 2,6-dimethyl-4-heptanone (S54), with binding affinities (ΔG) of -5.08, -5.06, and -4.90 kcal/mol, respectively. MD simulations further showed that the selected metabolites stabilized the ER-α-metabolite complex, with the 2,6-dimethyl-4-heptanone (S54) metabolite demonstrating the most negative total MM-GBSA energy value (ΔG = -22.98 kcal/mol), indicating a strong and stable binding interaction. Conclusion: 2,6-Dimethyl-4-heptanone, a metabolite from milk kefir, showed promising potential as a candidate for further development as a breast cancer treatment, offering a novel alternative to conventional therapies.
Andriansyah et al. (Thu,) studied this question.